(AOF) – Sartorius Stedim Biotech announces the launch of an offering of new shares for an amount of approximately 1.2 billion euros, with elimination of shareholders’ preferential subscription rights through accelerated book construction orders. The price of the placement of the capital increase should be announced at the latest before the start of trading on Euronext Paris on or around February 7. Settlement and delivery of the capital increase should take place on or around February 9, indicates a press release from the pharmaceutical industry supplier.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
